A pilot, phase II, multicenter, open-label, prospective evaluation of docetaxel and bevacizumab +/- trastuzumab in the first-line treatment of patients with metastatic breast cancer.
Phase of Trial: Phase II
Latest Information Update: 22 Aug 2012
At a glance
- Drugs Bevacizumab; Docetaxel; Trastuzumab
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 19 Apr 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
- 19 Apr 2012 Actual patient number is 73 as reported by ClinicalTrials.gov.
- 19 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.